Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy?

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 6748-6750

  Myers, Andrea P ^a,b   Meyerhardt, Jeffrey A ^a   Cantley, Lewis C ^b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; ENZYME ACTIVATION; GENE MUTATION; HUMAN; MORBIDITY; NOTE; PRIORITY JOURNAL; RADIATION ENTEROPATHY; RECTUM CANCER; RECTUM SURGERY; SEXUAL DYSFUNCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; COHORT STUDIES; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; MUTATION; RECTAL NEOPLASMS; RECURRENCE; TREATMENT OUTCOME;

EID: 72549092949     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2305     Document Type: Note

References (11)

1. He Y, Van't Veer LJ, Mikolajewska-Hanclich I, et al. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res 2009; 15:6956-6962
2. NIHc onsensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-1450
3. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-646 (Pubitemid 34936565)
4. Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993;36:564-572 (Pubitemid 23177416)
5. Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Lancet 1996; 348:1610-1614
6. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740
7. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004;22:1785-1796
8. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-2096
9. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9:550-562
10. Puzanov I, Nathanson KL, Chapman PB, et al. PLX4032, a highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial. J Clin Oncol 2009;27:9021.
11. O'Shaughnessy JA. Molecular signatures predict outcomes of breast cancer. N Engl J Med 2006;355:615-617 (Pubitemid 44200656)